Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JDWDD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
36924655 ADC 30
|
|||||
| Synonyms |
ADC 30
Click to Show/Hide
|
|||||
| Organization |
Seoul National University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.58
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
ADC-specific functional property(2027 Update)
Circulating Stability
| Incubation Time | 7day | Release | 0% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | Human serum | ||||
| Description |
The stability of the DEVD ADC in human serum was assessed by measuring the release of free exatecan over time. Maintaining stability in circulation is crucial for ADCs to prevent premature release of the cytotoxic payload, which can lead to off-target toxicity. The DEVD ADC was incubated in human serum at 37 °C, and samples were collected at various time points up to six days. Free exatecan levels were quantified using LC-MS/MS. The results showed that after six days, less than 1 %.
Click to Show/Hide
|
||||
References